136 related articles for article (PubMed ID: 2168839)
21. Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.
Sartori MT; Mares M; Zerbinati P; Stocco D; Girolami A
Haematologia (Budap); 1994; 26(1):17-27. PubMed ID: 7959371
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of murine leukemia virus infection as a model for thrombocytopenia of HIV/AIDS: mechanism of thrombocytopenia and modulation of thrombocytopenia by thrombopoietin.
Sullivan PS; McDonald TP
AIDS Res Hum Retroviruses; 1995 Jul; 11(7):837-42. PubMed ID: 7546911
[TBL] [Abstract][Full Text] [Related]
23. Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine.
Ruprecht RM; O'Brien LG; Rossoni LD; Nusinoff-Lehrman S
Nature; 1986 Oct 2-8; 323(6087):467-9. PubMed ID: 3463867
[TBL] [Abstract][Full Text] [Related]
24. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF.
Gallicchio VS; Hughes NK; Tse KF
Growth Regul; 1994 Jun; 4(2):41-7. PubMed ID: 7950902
[TBL] [Abstract][Full Text] [Related]
25. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells.
Bhalla K; Birkhofer M; Grant S; Graham G
Exp Hematol; 1989 Jan; 17(1):17-20. PubMed ID: 2783247
[TBL] [Abstract][Full Text] [Related]
26. Effect of antiviral treatments on the bone marrow in murine aids.
Brandi G; Carnevali A; Rossi L; Fraternale A; Schiavano GF; Magnani M
Blood Cells Mol Dis; 1995; 21(2):109-18. PubMed ID: 8846040
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of hematopoietic progenitor cell proliferation by ethanol in human immunodeficiency virus type 1 tat-expressing transgenic mice.
Prakash O; Rodriguez VE; Tang ZY; Zhou P; Coleman R; Dhillon G; Shellito JE; Nelson S
Alcohol Clin Exp Res; 2001 Mar; 25(3):450-6. PubMed ID: 11290858
[TBL] [Abstract][Full Text] [Related]
28. 3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS.
Tavares L; Roneker C; Johnston K; Lehrman SN; de Noronha F
Cancer Res; 1987 Jun; 47(12):3190-4. PubMed ID: 3034403
[TBL] [Abstract][Full Text] [Related]
29. Zidovudine therapy of HIV-associated thrombocytopenia: from MAIDS to AIDS.
Pomeroy C
J Lab Clin Med; 1993 Apr; 121(4):536-8. PubMed ID: 8454934
[No Abstract] [Full Text] [Related]
30. [Zidovudine in the treatment of HIV-related thrombocytopenia. A study of 11 cases].
Steidl L; Gussoni G; Montanari M; Crippa G
Recenti Prog Med; 1991; 82(7-8):397-8. PubMed ID: 1947405
[TBL] [Abstract][Full Text] [Related]
31. Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice.
Desai VG; Lee T; Moland CL; Branham WS; Von Tungeln LS; Beland FA; Fuscoe JC
Mitochondrion; 2009 Feb; 9(1):9-16. PubMed ID: 18824140
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of treatment with AZT of patients with AIDS and symptomatic HIV infection.
Cox PH; Martin MA; Styer CM; Beall GN
Nurse Pract; 1990 May; 15(5):36, 39-44. PubMed ID: 2342666
[TBL] [Abstract][Full Text] [Related]
33. The tetrapeptide AcSerAspLysPro (Seraspenide), a hematopoietic inhibitor, may reduce the in vitro toxicity of 3'-azido-3'-deoxythymidine to human hematopoietic progenitors.
Grillon C; Bonnet D; Mary JY; Lenfant M; Najman A; Guigon M
Stem Cells; 1993 Sep; 11(5):455-64. PubMed ID: 8241956
[TBL] [Abstract][Full Text] [Related]
34. Sustained elevation of platelet counts by long-term azidothymidine treatment of immunosuppressed mice.
Chow FP; Chen RB; Hamburger AW
J Lab Clin Med; 1993 Apr; 121(4):562-9. PubMed ID: 8454938
[TBL] [Abstract][Full Text] [Related]
35. Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp120 of human immunodeficiency virus.
McKallip RJ; Nagarkatti M; Nagarkatti PS
Toxicol Appl Pharmacol; 1995 Mar; 131(1):53-62. PubMed ID: 7878678
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model.
Basham T; Rios CD; Holdener T; Merigan TC
J Infect Dis; 1990 May; 161(5):1006-9. PubMed ID: 2157768
[TBL] [Abstract][Full Text] [Related]
37. In vivo evaluation of the anemia induced by azidothymidine (AZT) in a murine model of AIDS.
Chow FP; Hamburger AW
Eur J Haematol; 1991 Aug; 47(2):91-7. PubMed ID: 1889487
[TBL] [Abstract][Full Text] [Related]
38. Suppression of human immunodeficiency virus replication by 3'-azido-3'-deoxythymidine in various human hematopoietic cell lines in vitro: augmentation of the effect by lentinan.
Tochikura TS; Nakashima H; Kaneko Y; Kobayashi N; Yamamoto N
Jpn J Cancer Res; 1987 Jun; 78(6):583-9. PubMed ID: 3112074
[TBL] [Abstract][Full Text] [Related]
39. Liposomal encapsulation of 3'-azido-3'-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression.
Phillips NC; Skamene E; Tsoukas C
J Acquir Immune Defic Syndr (1988); 1991; 4(10):959-66. PubMed ID: 1890605
[TBL] [Abstract][Full Text] [Related]
40. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome.
Phillips NC; Tsoukas C
Blood; 1992 Mar; 79(5):1137-43. PubMed ID: 1371411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
